Best Vitamin K2 Supplements 2026

Always Take K2 with Fat

Vitamin K2 is a fat-soluble vitamin — its absorption from the gastrointestinal tract depends entirely on the presence of dietary fat to form chylomicrons for lymphatic transport. Taking K2 supplements with a fat-free meal or on an empty stomach dramatically reduces absorption. Always take your K2 supplement with a meal that contains fat — ideally a meal with at least 15–20g of fat. Products formulated in oil-based softgels (with coconut oil or other lipid carriers) partially mitigate this issue, but food co-ingestion remains important.

Pair K2 with Vitamin D3 for Synergistic Bone and Vascular Benefits

The K2+D3 combination is one of the most clinically rational supplement pairings available. Vitamin D3 significantly increases intestinal calcium absorption and stimulates osteocalcin gene expression in osteoblasts — but without adequate K2 to carboxylate the osteocalcin produced, the absorbed calcium may not be efficiently incorporated into bone. Additionally, high-dose vitamin D3 supplementation without K2 may theoretically increase the risk of calcium depositing in soft tissues and arteries, as the MGP activation that prevents this calcification depends on K2. For individuals supplementing D3 at doses of 2,000 IU or above, concurrent K2 supplementation (100–180mcg MK-7 or 1–2mg MK-4) is strongly advisable.

Third-Party Testing Is Critical for Fat-Soluble Vitamins

Fat-soluble vitamins — unlike water-soluble ones — accumulate in body fat and can reach potentially harmful levels with chronic overdosing. While vitamin K2 has an excellent safety record and no established tolerable upper intake level (UL) in healthy adults without bleeding disorders or anticoagulant use, accurate labeling matters. Prioritize products with NSF certification (Thorne), Informed Sport (Sports Research), or accessible Certificates of Analysis (Life Extension) over commodity products that rely solely on GMP compliance claims.

The Warfarin Interaction: Critical Safety Warning

Vitamin K2 directly antagonizes the mechanism of action of warfarin (Coumadin) and other vitamin K antagonist anticoagulants. Warfarin works by blocking vitamin K recycling, reducing the activity of clotting factors II, VII, IX, and X — supplemental K2 can unpredictably reverse this effect, potentially causing dangerous clotting in patients on anticoagulation therapy. Individuals taking warfarin, phenprocoumon, or acenocoumarol must NOT take vitamin K2 supplements without close physician supervision and INR monitoring. Patients stabilized on novel oral anticoagulants (NOACs/DOACs — apixaban, rivaroxaban, dabigatran) are generally not affected by vitamin K, but should still disclose any supplement changes to their prescribing physician.

Bone Mineral Density and Fracture Prevention

Vitamin K2's role in bone health centers on osteocalcin carboxylation. Osteocalcin is a protein produced by osteoblasts that anchors calcium into bone hydroxyapatite matrix — but it can only perform this function when gamma-carboxylated by vitamin K2-dependent enzymes. Undercarboxylated osteocalcin (ucOC) is a sensitive biomarker for K2 insufficiency and a predictor of fracture risk. In Japan, menatetrenone (MK-4 at 45mg/day) is an approved pharmaceutical treatment for osteoporosis, with multiple Phase III RCTs demonstrating significant reduction in vertebral fracture incidence. The Rotterdam Study, a prospective cohort of 4,800 adults followed for 10 years, found that the highest tertile of dietary K2 intake (primarily from cheese) was associated with 57% lower risk of aortic calcification and 26% reduced cardiovascular mortality, and 52% lower risk of severe aortic calcification versus the lowest tertile.

Research: Knapen et al. (2013), Osteoporos Int (Maastricht MK-7 RCT); Sato et al. (2005), Nutrition (MK-4 fracture RCT); Rotterdam Study: Geleijnse et al. (2004), J Nutr.

Arterial Calcification and Cardiovascular Health

Matrix Gla Protein (MGP) is the most potent known inhibitor of arterial calcification in the human body — and it requires vitamin K2-dependent gamma-carboxylation to function. Uncarboxylated MGP (ucMGP) is biologically inactive and cannot prevent calcium deposition in arterial walls. Population studies consistently find that high ucMGP levels — indicating K2 insufficiency — are associated with increased coronary artery calcification, arterial stiffness, and cardiovascular mortality. The EPIC-Norfolk cohort study found that each 10mcg/day increase in dietary K2 intake (but not K1) was associated with a 9% reduction in coronary heart disease incidence. A 2015 RCT found that 180mcg MK-7 daily for 12 weeks significantly reduced ucMGP levels and improved arterial stiffness measures (pulse wave velocity) in postmenopausal women — providing direct clinical evidence that supplemental MK-7 at achievable doses activates the cardiovascular calcification prevention mechanism.

Research: Geleijnse et al. (2004), J Nutr (Rotterdam); Gast et al. (2009), Nutr Metab Cardiovasc Dis (EPIC-Norfolk); Knapen et al. (2015), Thromb Haemost (arterial stiffness RCT).

Insulin Sensitivity and Metabolic Health

Osteocalcin has emerged as a surprising metabolic hormone beyond its structural bone role. Carboxylated osteocalcin regulates energy metabolism by stimulating insulin secretion from pancreatic beta cells and improving insulin sensitivity in muscle and adipose tissue. Animal studies show that osteocalcin-deficient mice develop metabolic syndrome features including visceral adiposity, glucose intolerance, and impaired insulin secretion. In humans, higher carboxylated osteocalcin levels are associated with better insulin sensitivity and lower type 2 diabetes risk in epidemiological studies. Whether K2 supplementation — by improving osteocalcin carboxylation — translates to clinically meaningful metabolic improvements in humans requires larger intervention trials, but the mechanistic pathway is established.

Research: Ferron et al. (2008), Cell; Kanazawa et al. (2011), Endocr J; Yoshida et al. (2008), J Bone Miner Res.

Natto and the Japanese Evidence Base

Japan provides a natural experiment in vitamin K2 and bone health: Japanese women have significantly lower hip fracture rates than Western European women despite similar or lower calcium intakes. Regions of Japan with high natto consumption (particularly eastern Japan) have significantly lower hip fracture rates than low-natto regions. Natto contains extraordinary amounts of MK-7 — approximately 850–1,000mcg per 100g serving, far exceeding any other food source. Epidemiological analyses of the Japan Nurses Health Study and regional Japanese data consistently find that higher dietary K2 intake (strongly correlated with natto consumption) is one of the most powerful predictors of bone fracture protection in Japanese women. This population-level evidence aligns with the RCT data on supplemental MK-4 and MK-7, providing convergent evidence for K2's clinical significance in bone health.

Research: Kaneki et al. (2001), Nutrition (regional Japan natto study); Tsugawa et al. (2008), Br J Nutr; Iwamoto et al. (2006), Clin Rheumatol.

General Bone & Cardiovascular Maintenance (Most Adults)

• MK-7 dose: 100–180mcg once daily with a fatty meal
• MK-4 dose: 500mcg–1mg, 2–3 times daily with meals
• Pair with: Vitamin D3 (2,000–5,000 IU daily) and adequate calcium from diet or supplementation
• Timeline: Bone density effects require 1–3 years; osteocalcin carboxylation improves within weeks of supplementation

Active Bone Density Support (Post-Menopausal Women, Osteopenia)

• MK-7 dose: 180mcg once daily — the dose validated in the Maastricht 3-year RCT
• MK-4 dose: 1–5mg daily in divided doses; Japanese pharmaceutical dose is 45mg/day (available by prescription in Japan, but widely available as a supplement in the US at lower doses)
• Stack with: Calcium (1,000–1,200mg/day from diet + supplements), Vitamin D3 (2,000–4,000 IU), and Magnesium (300–400mg) — the four cornerstones of bone mineral density support
• Monitor: Bone density DEXA scans every 1–2 years to assess response; carboxylated osteocalcin blood tests can track K2 status

Arterial Calcification Prevention (Cardiovascular Health Focus)

• MK-7 dose: 180mcg daily — the dose shown to reduce ucMGP and improve arterial stiffness in RCTs
• Key biomarker: dp-ucMGP (dephosphorylated-uncarboxylated Matrix Gla Protein) — the most direct blood test for K2 status and arterial calcification risk; levels above 500 pmol/L suggest meaningful K2 deficiency
• Stack with: Vitamin D3 (improves MGP gene expression), CoQ10 (100–200mg for arterial health and oxidative stress reduction), and omega-3 fatty acids for comprehensive cardiovascular support

The Optimal Bone Stack

For comprehensive bone health support, the evidence-based stack combines: Vitamin K2 MK-7 180mcg (osteocalcin carboxylation and MGP activation) + Vitamin D3 2,000–5,000 IU (calcium absorption and osteocalcin production) + Calcium 1,000–1,200mg/day (the mineral substrate for bone hydroxyapatite) + Magnesium 300–400mg (required for vitamin D activation and over 300 enzymatic reactions in bone metabolism). These four nutrients work as interdependent co-factors — optimizing all four together is more effective than supplementing any single one in isolation.